Alzheimer’s disease is one of the most common causes of dementia and memory loss in older adults. It slowly damages the brain and affects a person’s ability to remember, think clearly, and carry out everyday tasks.
For many years, scientists believed that the disease begins mainly with the loss of connections between brain cells. However, new research suggests that the earliest changes in Alzheimer’s may be very different from what experts once thought.
A team of neuroscientists at King’s College London has discovered that the early stage of Alzheimer’s disease may actually involve too many connections between brain cells rather than too few. Their study, published in the journal Translational Psychiatry, also found that a drug currently being tested for cancer may help correct these early brain changes.
The human brain contains billions of nerve cells called neurons. These cells communicate with each other through small contact points called synapses. Through these connections, neurons pass electrical and chemical signals that allow us to think, learn, and form memories. In healthy brains, these connections are carefully organized and balanced.
In Alzheimer’s disease, abnormal proteins build up in the brain. One of the most important of these proteins is called amyloid‑beta. This protein can collect into sticky clumps known as plaques that surround nerve cells. Scientists have long believed that these plaques damage neurons and eventually cause them to die.
However, the new study shows that amyloid‑beta may start affecting the brain long before large plaques appear. The researchers discovered that even small amounts of this protein can cause brain cells to form unusually high numbers of connections with each other. This condition is known as hyperconnectivity.
The researchers found that exposing brain cells to low levels of amyloid‑beta for about five days was enough to trigger this excessive connectivity. The pattern they observed closely resembled the brain activity seen in people with mild cognitive impairment, often called MCI. Mild cognitive impairment is considered an early stage of Alzheimer’s disease.
People with MCI may notice small problems with memory or thinking, but their symptoms are usually not severe enough to interfere with daily life.
According to the scientists, this finding may change how researchers understand the development of Alzheimer’s disease. Instead of starting with the loss of synapses, the disease may begin with too many poorly organized connections between neurons. Over time, this unstable network may make the brain more vulnerable to damage.
The research team also discovered that amyloid‑beta affects many other proteins in the brain. They identified changes in 49 different proteins that appear to work together to increase the number of neural connections. Some of these proteins help control how cells produce other proteins needed for communication between neurons.
One interesting observation was that amyloid‑beta may create a kind of self‑reinforcing cycle. The protein appears to trigger conditions that encourage the production of even more amyloid‑beta. This loop could gradually worsen the abnormal changes in the brain and eventually lead to the more severe stages of Alzheimer’s disease.
While studying these processes, the researchers also explored whether any drugs could stop the abnormal increase in brain connectivity. They focused on a biological pathway controlled by a protein target called MAP kinase interacting kinase, often shortened to MNK. This pathway helps regulate how certain proteins are produced inside cells.
The scientists tested a drug called eFT508, which targets the MNK pathway. This medication is currently being studied in clinical trials as a treatment for some types of cancer. It has not previously been tested as a treatment for Alzheimer’s disease.
When the researchers applied the drug to brain cells exposed to amyloid‑beta, they observed encouraging results. The drug prevented the excessive increase in connections between neurons. It also helped restore about 70 percent of the abnormal protein changes caused by amyloid‑beta exposure.
These findings suggest that drugs targeting this pathway may help stabilize early brain networks before serious damage occurs. If confirmed in future studies, such treatments might help protect memory and thinking abilities in people with early Alzheimer’s disease or mild cognitive impairment.
However, experts emphasize that this research is still at a very early stage. The experiments were conducted using brain cells in laboratory models rather than human patients. Before any new treatment can be developed, the results must first be confirmed in animal studies and then carefully tested in human clinical trials.
Even so, the study provides an important new perspective on Alzheimer’s disease. It suggests that the earliest stage of the illness may involve overactive and poorly organized neural networks rather than immediate cell loss. This idea may help scientists design treatments aimed at stabilizing brain circuits before major damage occurs.
Another promising aspect of this research is the concept of drug repurposing. Instead of developing an entirely new medication, scientists may be able to use drugs that are already being tested or approved for other diseases. Because these drugs have already undergone safety testing, the process of adapting them for new uses may be faster.
Overall, the study highlights a new way of understanding how Alzheimer’s disease may begin and how it might eventually be treated. If future research confirms these findings, targeting early brain hyperconnectivity could become an important strategy for slowing or preventing memory loss.
At the same time, the study has limitations. The research focused on cellular models and short‑term experiments, so it cannot yet show whether the same processes occur in the human brain over many years.
Alzheimer’s disease is also a complex condition influenced by many genetic, environmental, and lifestyle factors. Because of this complexity, no single treatment is likely to solve the entire problem.
Nevertheless, the work provides valuable clues about the earliest biological changes in Alzheimer’s disease. By identifying how amyloid‑beta disrupts communication between neurons and by showing that these changes may be reversible, the study opens a promising path for future research and possible therapies.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
